ReShape Submits Dual-Balloon Weight-Loss System PMA
This article was originally published in The Gray Sheet
Executive Summary
The system, which has been marketed in Europe since 2011, is the first non-surgical weight-loss device to meet its primary endpoints in a U.S., randomized sham-controlled pivotal trial, the firm said.
You may also be interested in...
News Briefs: Panel Supports Cochlear Implant; ReShape Duo Trial Update; Medtronic’s D-fib Lead Software
FDA panel supports cochlear implant device. ReShape Medical’s ReShape Duo intragastric balloon meets its primary efficacy endpoints in the REDUCE trial. Medtronic gains FDA approval of defibrillator lead software. More news.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.